VMT treatment launched in Denmark and Sweden

Article

JETREA (ThromboGenics, Leuven, Belgium) has launched in Denmark and Sweden with roll out of the drug to follow shortly in Finland and Norway. These launches will be performed by ThromboGenics partner, Alcon.

JETREA (ThromboGenics, Leuven, Belgium) has launched in Denmark and Sweden with roll out of the drug to follow shortly in Finland and Norway. These launches will be performed by ThromboGenics partner, Alcon.

Earlier this year, JETREA was approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, by the European Commission and since then it has been launched in the UK and Germany, in Europe.

Dr Patrik de Haes, CEO of ThromboGenics, stated, “We look forward to further launches across the Nordic region and other countries to ensure that patients are able to have access to the first pharmacological treatment for VMT including when associated with macular hole of diameter less than or equal to 400 microns.”

If you would like more information on JETREA and its availability please visit ThromboGenic’s website.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.